What happened with KRYS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Krystal Biotech’s only commercial product, VYJUVEK, treats dystrophic epidermolysis bullosa (DEB) and is applied to the skin. The company produces the gene-delivery component at its ANCORIS facility, while a third party supplies the sterile gel mixed with it. Other genetic medicines remain in clinical development.
Specialty pharmacies buy VYJUVEK and prepare it for administration at a healthcare professional’s office or a patient’s home; hospitals and specialty distributors also buy it for hospital-based treatment. These customers pay Krystal for the drug, while government and private health coverage is essential for most patients to afford treatment. A single U.S. customer accounts for most product revenue.
Krystal manages commercialization directly in the United States, major European markets and Japan, and uses specialty distributors elsewhere. VYJUVEK is approved in the United States, European Union and Japan, but wider access depends on local approvals, pricing and reimbursement arrangements. Pricing negotiations remain ongoing in Germany and France, where sales have already begun. Patients must undergo genetic testing before receiving VYJUVEK, and sales depend on physicians prescribing it and payors covering treatment.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Krystal Biotech’s results hinge on VYJUVEK adoption and reimbursement for DEB; watch Chiesi’s approved Filsuvez, another treatment option not represented in this list.
Abeona Therapeutics competes for patients who could receive Krystal Biotech’s topical VYJUVEK: its ZEVASKYN treats recessive DEB wounds with sheets grown from patients’ own gene-corrected skin cells and applied surgically, with insurers covering treatment. Watch how many patients Abeona treats through its qualified centers as a sign of uptake of this alternative to VYJUVEK.
Krystal Biotech, Inc. earningsThis company
Krystal Biotech's report will show whether VYJUVEK sales are growing in newly launched markets as well as in the U.S., and whether the business is becoming less dependent on one U.S. customer.
Read VYJUVEK net product revenue alongside sales by market, especially progress in Germany, France and Japan, and whether U.S. revenue remains concentrated in one customer. More sales in new markets with a lower U.S. customer concentration would show that additional channels and countries are reaching patients; if revenue still rests mainly on one U.S. customer, growth remains exposed to a single purchasing route.
Abeona Therapeutics Inc. earningsABEO
Abeona Therapeutics' report will show how many patients its qualified centers treated with ZEVASKYN, indicating how much this surgical alternative competes with VYJUVEK for patients.
Compare the number of patients Abeona treats with ZEVASKYN and the use of its qualified centers with Krystal Biotech's VYJUVEK sales and how patients receive it. More ZEVASKYN patients would show that this surgical alternative is reaching more people and could draw from the patients VYJUVEK can serve; few would indicate limited observed competition, not prove stronger demand for VYJUVEK.
